Oculis HoldingOCS
OCS
About: Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Employees: 36
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
0.76% less ownership
Funds ownership: 7.98% [Q2] → 7.22% (-0.76%) [Q3]
7% less capital invested
Capital invested by funds: $39.8M [Q2] → $36.9M (-$2.82M) [Q3]
9% less funds holding
Funds holding: 11 [Q2] → 10 (-1) [Q3]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$28
23%
upside
Avg. target
$29
28%
upside
High target
$30
32%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Daniil Gataulin 29% 1-year accuracy 10 / 34 met price target | 23%upside $28 | Buy Maintained | 7 Jan 2025 |
HC Wainwright & Co. Yi Chen 39% 1-year accuracy 61 / 156 met price target | 32%upside $30 | Buy Reiterated | 6 Jan 2025 |
Financial journalist opinion
Based on 3 articles about OCS published over the past 30 days
Positive
Seeking Alpha
1 day ago
Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care
Oculis' main value driver appears to be OCS-01, which targets a respectable $4 billion DME TAM with its non-invasive eye drops. Eye injections are tough on patients, so this bodes well for OCS-01. OCS-05 and OCS-02 also target interesting TAMs in neuro-ophthalmology and DMD. OCS's cash runway should last until late 2026, but if they don't generate an FDA-approved product soon, it could become an issue for shareholders.
Neutral
GlobeNewsWire
2 weeks ago
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
Neutral
GlobeNewsWire
2 weeks ago
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
ZUG, Switzerland, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced positive topline results with OCS-05 in the Phase 2 ACUITY trial, which met the primary endpoint of safety and achieved statistical significance on several key efficacy-based secondary endpoints. The trial evaluated the safety, tolerability and efficacy of OCS-05, a neuroprotective candidate, in patients with acute optic neuritis.
Neutral
GlobeNewsWire
1 month ago
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, Dec. 06, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
Neutral
GlobeNewsWire
1 month ago
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
ZUG, Switzerland, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.
Neutral
GlobeNewsWire
1 month ago
Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities
ZUG, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The attached notification relates to a one-time equity incentive award issued to a director of the Company for his independent services as a consultant to the Company.
Neutral
GlobeNewsWire
2 months ago
Oculis to Present at the Stifel 2024 Healthcare Conference
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis' management will be present at the Stifel 2024 Healthcare Conference being held on November 18-19, 2024 at the Lotte New York Palace Hotel in New York, NY.
Neutral
GlobeNewsWire
2 months ago
Oculis to Present at the Stifel 2024 Healthcare Conference
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis' management will be present at the Stifel 2024 Healthcare Conference being held on November 18-19, 2024 at the Lotte New York Palace Hotel in New York, NY.
Negative
Zacks Investment Research
2 months ago
Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.38 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
ZUG, Switzerland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced results for the quarter ended September 30, 2024, and provided an overview of the Company's progress.
Charts implemented using Lightweight Charts™